For Public Health & Municipalities
Prevention as public infrastructure
Perimenopause is not only an individual health issue. It is a window where cardiometabolic, mental health, sleep and musculoskeletal risks can begin to shift, with consequences for prevention, workforce participation, health equity and avoidable system burden.
How we work together
Public prevention and equitable access partner. You help explore how Scita can support earlier navigation, equitable access and population-level prevention, especially once clinical certification and evidence generation are in place.
In the Nordics, good health care is something we fund together. Scita is built toward the clinical standard and data protection architecture that public adoption requires, with EU-sovereign infrastructure and GDPR-first design.
What you get
- Municipal prevention pilots that generate population-level engagement evidence
- A pathway toward publicly funded access once clinical certification is in place
- Support for earlier prevention before risks become more complex and costly
- Alignment with WHO/Europe public health innovation work
Grounded in public work
- WHO/Europe
- Scita is a participating organisation in the WHO/Europe Public Health Innovation Platform.
- The Nordic Charter for Women’s Health 2040
- Our founder, Julia Persson, is its founding architect. The article on its method was published in The Lancet Obstetrics, Gynaecology, & Women’s Health.
- The CharterThe article in The Lancet
- The European Health Data Space
- Julia Persson sits on the External Advisory Board of myHealth@myHands, an EU Digital Europe Programme project connecting the European Digital Identity Wallet with the European Health Data Space.
- Built on public guidance
- The rules on hormone therapy are written from the Danish and Swedish national guidance, rule by rule. Every link on the free map names its source, and its Work reading draws on Dansk Standard’s guide on menopause at work.
- The regulated path
- Built toward MDR Class IIa certification, in dialogue with a notified body. A randomised controlled trial is designed with a Nordic medical university.
€111bn
Why this matters
Cardiovascular disease costs EU health systems around €111 billion a year in direct healthcare expenditure.
Source: European Commission, Knowledge for Policy
Earlier prevention matters.
Let’s talk
Tell us about your work, and we will come back to you.
Partners can help fund access, evidence and care pathways, but they do not control her data, her guidance or her decisions.
Other partners